Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 39% Improvement Relative Risk c19early.org/fm Zangeneh et al. Famotidine for COVID-19 ICU Is very late treatment with famotidine beneficial for COVID-19? Retrospective study in Iran Lower mortality with famotidine (p=0.014) Zangeneh et al., Obesity Medicine, doi:10.1016/j.obmed.2022.100420 Favors famotidine Favors control
Survival analysis based on body mass index in patients with Covid-19 admitted to the intensive care unit of Amir Al-Momenin Hospital in Arak – 2021
Zangeneh et al., Obesity Medicine, doi:10.1016/j.obmed.2022.100420
Zangeneh et al., Survival analysis based on body mass index in patients with Covid-19 admitted to the intensive care unit of.., Obesity Medicine, doi:10.1016/j.obmed.2022.100420
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 193 ICU patients in Iran, showing lower mortality with famotidine treatment.
This study includes vitamin C, vitamin D, zinc, remdesivir, and famotidine.
risk of death, 39.0% lower, HR 0.61, p = 0.01, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zangeneh et al., 13 May 2022, retrospective, Iran, peer-reviewed, 3 authors.
Contact: mor.zangene62@gmail.com, touraj1416@gmail.com, a.sharifi1983@gmail.com, a_sharifi@goums.ac.ir.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFamotidineAll
Survival analysis based on body mass index in patients with Covid-19 admitted to the intensive care unit of Amir Al-Momenin Hospital in Arak – 2021
Morteza Zangeneh, Touraj Valeh, Amrollah Sharifi
Obesity Medicine, doi:10.1016/j.obmed.2022.100420
Introduction: The potential risk of obesity on the severity of COVID-19 has been proposed. The main purpose of this study was to investigate the effect of BMI on the survival rate of COVID-19 patients admitted to the ICU. Methods & materials: Patients with COVID-19 admitted to ICU were included. Gender, height, weight, BMI, age, underlying disease status, prescribed drugs and nutritional supplements, and clinical and laboratory parameters at the beginning of admission were recorded. Death or discharge from the ICU and the days elapsed to these events were also reviewed and recorded. Data analysis was performed using the Cox regression model. Results: assessing 193 patients showed that BMI was not related to the survival rate even after adjusting for other potential confounding variables. It was shown that arterial oxygen saturation and taking Famotidine were the significant factors determining the time to event in these patients. Conclusion: The BMI at the time of ICU admission has no effect on survival rate and time to event in COVID-19 infected patients admitted to ICU.
Declaration of competing interest None.
References
Abbas, Fathy, Fawzy, Salem, Shawky et al., Obesity and susceptibility to severe outcomes following respiratory viral infection, Obes. Med
Andersen, Murphy, Fernandez, Impact of obesity and metabolic syndrome on immunity, Adv. Nutr
Brennan, Nadella, Zhao, Dima, Jordan-Martin et al., Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial, Gut
Cheng, Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?, Med. Drug Discov
Chiu, Shen, Lo, Chiu, Chen et al., Effect of famotidine on hospitalized patients with COVID-19: a systematic review and metaanalysis, PLoS One
Chowdhury, Alam, Rabbi, Rahman, Reza, Does higher body mass index increase COVID-19 severity? A systematic review and metaanalysis, Obes. Med
De Almeida Brasiel, The key role of zinc in elderly immunity: a possible approach in the COVID-19 crisis, Clin. Nutr. ESPEN
De Siqueira, Almeida, Zica, Brum, Barcelo et al., Impact of obesity on hospitalizations and mortality, due to COVID-19: a systematic review, Obes. Res. Clin. Pract
Emami, Akbari, Basirat, Zare, Javanmardi et al., The role of comorbidities on mortality of COVID-19 in patients with diabetes, Obes. Med
Fresán, Guevara, Elía, Albéniz, Burgui et al., Independent role of severe obesity as a risk factor for COVID-19 hospitalization: a Spanish population-based cohort study, Obesity
Giacomelli, Ridolfo, Milazzo, Oreni, Bernacchia et al., 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study, Pharmacol. Res
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy, JAMA
Houdek, Griffin, Ferguson, Wunder, Morbid obesity increases the risk of postoperative wound complications, infection, and repeat surgical procedures following upper extremity limb salvage surgery for soft tissue sarcoma, Hand (N Y)
Huang, Lu, Huang, Wang, Ling et al., Obesity in patients with COVID-19: a systematic review and meta-analysis, Obes. Res. Clin. Pract
Huang, Wang, Zheng, Liu, Chen et al., Letter to the Editor: obesity hypoventilation syndrome and severe COVID-19, Metabolism
Kang, Mortality rate of infection with COVID-19 in Korea from the perspective of underlying disease, Disaster Med. Public Health Prep
Li, Li, Zhang, Wang, Lighter et al., Obesity in patients younger than 60 Years is a risk factor for COVID-19 hospital admission, Infect. Dis. Poverty
Loffredo, Lucero, Chen, O'connell, Bergqvist et al., The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication, Sci. Rep
Louie, Acosta, Samuel, Schechter, Vugia et al., A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1), Clin. Infect. Dis
Mizumoto, Kagaya, Zarebski, Chowell, Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Euro Surveill
Muscogiuri, Pugliese, Barrea, Savastano, Colao, Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection, Metabol. Clin
Palaiodimos, Kokkinidis, Li, Karamanis, Ognibene et al., Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, Metabolism
Pranata, Lim, Yonas, Vania, Lukito et al., Body mass index and outcome in patients with COVID-19: a dose-response metaanalysis, Diabetes Metab
Rojas-Osornio, Cruz-Hernandez, Drago-Serrano, Campos-Rodriguez, Immunity to influenza: impact of obesity, Obes. Res. Clin. Pract
Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med
Rychter, Zawada, Ratajczak, Dobrowolska, Krela-Kazmierczak, Should patients with obesity be more afraid of COVID-19?, Obes. Rev
Sartaj Sohrab, Atkinson, Alawi, Azhar, Viral infection and obesity: current status and future prospective, Curr. Drug Metabol
Sattar, Mcinnes, Mcmurray, Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms, Circulation
Shrestha, Charkviani, Musurakis, Kansakar, Devkota et al., Type 2 diabetes is associated with increased risk of critical respiratory illness in patients COVID-19 in a community hospital, Obes. Med
Skalny, Rink, Ajsuvakova, Aschner, Gritsenko et al., Zinc and respiratory tract infections: perspectives for COVID-19, Int. J. Mol. Med
Sureshchandra, Marshall, Messaoudi, Impact of pregravid obesity on maternal and fetal immunity: fertile grounds for reprogramming, J. Leukoc. Biol
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Yates, Razieh, Zaccardi, Davies, Khunti, Obesity and risk of COVID-19: analysis of UK biobank, Prim. Care Diabetes
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit